CA2358885C - Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them - Google Patents
Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them Download PDFInfo
- Publication number
- CA2358885C CA2358885C CA002358885A CA2358885A CA2358885C CA 2358885 C CA2358885 C CA 2358885C CA 002358885 A CA002358885 A CA 002358885A CA 2358885 A CA2358885 A CA 2358885A CA 2358885 C CA2358885 C CA 2358885C
- Authority
- CA
- Canada
- Prior art keywords
- dichlorophenyl
- bromophenyl
- ethylpyrazole
- compound
- solvates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/78—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
- C07C251/80—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
Abstract
The invention concerns N-piperidino-5-(4-bromophenyl)-1- (2,4dichlorophenyl)-4-ethylpyrazole-3-carboxamide of formula (I), (See formula I) the salts and solvents thereof which are powerful antagonists of cannabinoid CB 1 receptors. The method for preparing them consists in reacting a functional derivative of 5-(4- brothophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine with subsequent optional salification.
Description
PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION
AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
The present invention relates to a novel pyrazole derivative, to its salts and to the solvates thereof, to a process for their preparation and to pharmaceutical compositions containing them.
Patent applications EP-A-576 357, EP-A-658 546 and WO-97/19063 describe pyrazole derivatives with affinity for cannabinoid receptors.
More particularly, patent appliction EP-A-656 354 describes N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, also known as SR 141 716, and the pharmaceutically acceptable salts thereof which have very good affinity for the central cannabinoid receptors.
Compounds similar to SR 141716 have been described in the literature, in particular N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, referred to hereinbelow as compound A, which is described by B.F. Thomas et al.
in J. Pharm. Exp. Therap., 1998, 285, 285-292.
The effects of cannabinoids are due to an interaction with specific high-affinity receptors present at the central level (Devane et al., Mol.
Pharmacol., 1988, 34, 605-613) and at the peripheral level (Nye et al., Pharmacol. and Experimental Ther., 1985, 234, 784-791 ; Kaminski et al., 1992, Mol.
Pharmacol., 42, 736-742 ; Munro et al., Nature, 1993, 365, 61-65) .
Characterization of the receptors was made possible by the development of synthetic ligands specific for cannabinoid receptors, such as the agonists WIN 55212-2 (J. Pharmacol. Exp. Ther., 1993, 264, 1352-1353) or CP 55,990 (J. Pharmacol. Exp. Ther., 1988, 247, 1046-1051). The pharmacology of the CB1 and CB2 cannabinoid receptor subtypes is outlined in Pharmacol. Ther., 1997, 79, 129-130.
A novel N-piperidino-3-pyrazolecarboxamide derivative has now been found which has very good affinity for the CB1 subtype of cannabinoid receptors (CB,_ receptors) with long-lasting action, which is useful in the therapeutic fields in which cannabinoids are known to be involved.
According to one of its aspects, the present invention relates to N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, of formula:
HSC, CO-NH- N\
~ N~ ,,~~N
CI
Br (I) ci "' 3 to its pharmaceutically acceptable salts and to the solvates thereof.
According to another of its aspects, the present invention relates to a process for preparing compound (I) above, its salts and the solvates thereof, characterized in that a functional derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid, of formula:
COOH
N~N
CI
Br (II) CI
is treated with 1-aminopiperidine, in an organic solvent and in the presence of a base; and the compound thus obtained is optionally converted into one of its salts or one of the solvates thereof.
The reaction is carried out in basic medium, for example in the presence of triethylamine in an inert solvent such as dichloromethane or tetrahydrofuran.
Functional derivatives of the acid (II) which may be used are the acid chloride, the anhydride, a mixed anhydride, a Ci-C4 alkyl ester in which the alkyl is straight or branched, an activated ester, for example the p-nitrophenyl ester, or the suitably activated free acid, for example activated with N,N-dicyclohexylcarbodiimide or with benzotriazole-N-oxotris(dimethylamino)phosphonium (BOP) hexafluorophosphate.
Thus, by means of the process according to the invention, it is possible to react the acid chloride of formula (II) obtained by reacting thionyl chloride with the acid of formula (II) in an inert solvent, such as benzene or toluene, or a chlorinated solvent (for example dichloromethane, dichloroethane or chloroform), an ether (for example tetrahydrofuran or dioxane), or an amide (for example N,N-dimethylformamide) under an inert atmosphere, at a temperature of between 0°C and the reflux point of the solvent.
One variant of the procedure consists in preparing the mixed anhydride of the acid of formula (II) by reacting ethyl chloroformate with the acid of formula (II), in the presence of a base such as triethylamine.
The acid of formula (II) can be prepared according to the reaction scheme described below, in which:
LiHMI~S = lithium hexamethyldisilazide NBS = N-bromosuccinimide.
O I) LiFBvIDS ~ ~ O' LQ
Br Br Et 2) (COzEt)2 CH COZEt ~ W
(IU) ~ ~ Cl CH
OEt ~ ~ C1 NON AcOH
Cl ~ Br / \ O N- NH CI
Br ~ ~ ~ (IV) CH3 C02Et (V) NBS
CH, MeZCuLi I) (VI) ~ KOH/McOH
HZO
(II) 5 The first step is carried out according to J. Heterocyclic. Chem., 1989, 26, 1389. In the penultimate step, the conversion of the 4-bromomethyl substituent of the pyrazole into 4-ethyl is carried out according to J. Am. Chem. Soc., 1968, 90, 5615.
The 1-aminopiperidine used is a commercial product.
'- 6 The ester of formula (VII) and the acid of formula (II) can be prepared according to another process which constitutes a further subject of the present invention.
This process is illustrated by the reaction scheme below, in which Alk represents a (C1-C6)alkyl and represents an ethyl.
O O
1 ) LiHMDS
Br / \ ~-(C~)z-CH3 OAIk Br / \ COzAIk O Et O (VIII) N
CI
O N-' NH C1 HCI
Br ~ \ CO.,AIk Et (IX) .. (1I) (VII) This process is characterized in that an alkyl ester, preferably the ethyl ester, of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid is prepared by cyclization of an alkyl ester, preferably the ethyl ester, of 3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)-hydrazono)pentanoic acid (IX).
This reaction is carried out in a protic solvent such as an alcohol, for example a C1-Ca alcohol, preferably ethanol, at a temperature of between room temperature and 80°C, preferably in reluxing ethanol.
According to the invention, the alkyl ester, preferably the ethyl ester, of 3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)hydrazono)pentanoic acid is prepared by the action of a 2,4-dichlorophenylhydrazine salt, preferably the hydrochloride, on an alkyl ester, preferably the ethyl ester, of 4-bromobenzoyl-2-oxopentanoic acid (VIII).
The reaction is carried out in a protic solvent, for example a C1-C4 alcohol, preferably ethanol.
According to the invention, the alkyl ester, preferably the ethyl ester, of 4-bromobenzoyl-2-oxopentanoic acid is prepared by the action of LiE~IDS
and then of an alkyl ester, preferably the ethyl ester, of 2-(1-imidazolyl)-2-oxoacetic acid on bromobutyrophenone.
The reaction is carried out in an organic solvent such as an aromatic solvent or an ether, preferably methyl tent-butyl ether. The first step of this reaction is carried out at low temperature, for example at a temperature between 0°C and -60°C, preferably at a temperature in the region of -20°C; the second step is carried out at a temperature of between room temperature and -20°C, preferably at room temperature.
Thus, according to Scheme 2, the preparation of an alkyl ester of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid (VII) is carried out starting with 4-bromobenzoyl-2-oxopentanoic acid (VIII) by the action of a 2,4-dichlorophenylhydrazine salt, followed by cyclization.
Bromobutyrophenone is commercially available.
The ethyl ester of 2-(1-imidazolyl)-2-oxoacetic acid is described and prepared according to J. Org. Chem., 1981, 46 (1), 211-213.
The present invention also comprises a process for preparing an alkyl ester, preferably the ethyl ester, of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid, from 4-bromobenzoyl-2-oxopentanoic acid, by the action of a 2,4-dichlorophenylhydrazine salt, preferably the hydrochloride, in a protic solvent, for example a C1-CQ alcohol, preferably ethanol. The " 9 reaction is carried out at a temperature of between room temperature and 80°C, preferably in reluxing ethanol.
The compounds of formula:
O O
Br ~ \ COZAIk (VIII) Et CI
O ~1-- NH Cl Br ~ \ CY 'COZAIk (IX) IEt in which Alk represents a (C1-C6)alkyl are novel and form part of the invention. Preferably, Alk represents an ethyl.
The compound of formula (I) obtained by the process according to the invention is isolated, in the form of the free base or of a salt or solvate, according to the conventional techniques.
The pharmaceutically acceptable salts of the compound of formula (I) comprise the addition salts with acids, such as the hydrochloride, the hydrobromide, the sulphate, the hydrogen sulphate, the dihydrogen phosphate, the methanesulphonate, the methyl sulphate, the oxalate, the maleate, the fumarate, the 1~
2-naphthalenesulphonate, the glyconate, the gluconate, the citrate, the isethionate, the para-toluenesulphonate or the succinate.
The compound of formula (I) can be isolated in the form of one of its salts, for example the hydrochloride or the oxalate; in this case, the free base can be prepared by neutralizing the said salt with an inorganic or organic base, such as sodium hydroxide or ammonium hydroxide, triethylamine or an alkali metal carbonate or bicarbonate such as sodium or potassium carbonate or bicarbonate, and converted into another salt such as the methanesulphonate, fumarate or 2-naphthalenesulphonate.
When the compound of formula (I) is obtained in the form of the free base, the salification is carried out by treatment with the acid chosen in an organic solvent. By treating the free base, dissolved, for example, in an ether such as diethyl ether or in acetone, with a solution of the acid in the same solvent, the corresponding salt is obtained and is then isolated according to the conventional techniques.
The compounds of formula (I) have very good in vitro affinity for the CB1 cannabinoid receptors, under the experimental conditions described by Devane et al., Mol. Pharmacol., 1988, 34, 605-613.
Thus, the compound according to the invention has very strong affinity for human CB1 cannabinoid receptors (Ki = 5.4 nM) which compares favourably with that of SR 141716 for the same receptors, determined under the same conditions (Ki = 34 nM).
The compound according to the invention was also compared with N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, (compound A). The affinity of this compound for human CB1 cannabinoid receptors, measured under the same conditions, is reflected by a Ki value of 8 nM.
Moreover, the duration of occupation of the Cel receptors present in the brain by the 3 compounds below was compared:
- the compound of formula (I) according to the invention, - SR 141716, - compound A.
The study was performed in vivo in mice, after oral administration of each of the compounds at a dose of 10 mg/kg, according to the technique described in M. Rinaldi-Carmona et al., Life Sciences, 1995, 56, 1941-1947. The results obtained are collated in the table below.
mTnr c 'f $ of occupation of the receptors 1 hour 24 hours Compound of 82~ 44~
formula (I) SR 141716 69~ 4~
Compound A 89~ 4$
Surprisingly, it is observed that the compound of formula (I) according to the invention is the only compound which shows appreciable occupation (44~) 24 hours after its administration.
Moreover, the antagonist nature of the compound of formula (I) was demonstrated by the results obtained in models of adenylate-cyclase inhibition as described in M. Rinaldi-Carmona et al., J. Pharmacol.
Exp. Ther., 1996, 278, 871-878.
More particularly, the compound of the present invention, in its native form or in the form of one of its pharmaceutically acceptable salts, is a powerful and selective antagonist of the CB1 cannabinoid receptors.
The antagonist nature of the compound according to the invention, as well as its good penetration into the central nervous system, are confirmed by the results obtained in the model of antagonism of the hypothermia induced with a cannabinoid receptor agonist. Thus, the compound of formula (I) according to the invention antagonizes the hypothermia induced with WIN 55212-2 in mice, with an oral EDSO of 0.3 mg/kg in the test described by Pertwee R.G. et al. in Marijuana, 84, Ed. Harvey, D.Y.
Oxford IRL Press, 1985, 263-277. In this test, the activity and the duration of action of 3 compounds were compared. The results obtained are collated in the table below:
Antagonism of the hypothermia induced Duration of action oral EDSOoral 24 h dose Compound of formula 0.3 mg/kg1 mg/kg active (I) SR 141716 0.4 mg/kg1 mg/kg not active 10 mg/kg active Compound A 0.3 mg/kg1 mg/kg not active 10 mg/kg active It is found that the compound of the present invention has an EDSo which is comparable with those of the compounds of the prior art, but its duration of action is markedly longer.
Thus, whereas 24 hours after their administration, SR 141716 and compound A are only active at a dose of 10 mg/kg/p.o., the compound of formula (I) according to the invention is active 24 hours after its administration, at a dose 10 times lower (1 mg/kg/p.o.).
The long-lasting action of the compound of formula (I) according to the invention is particularly noteworthy and represents an important advantage for its use as a medicinal product.
The toxicity of compounds (I) is compatible with their use as medicinal products.
According to another of its aspects, the present invention relates to the use of a compound of formula (I), or one of the pharmaceutically acceptable salts or solvates thereof, for the preparation of medicinal products intended for treating diseases involving the CB1 cannabinoid receptors.
For example, and in a non-limiting manner, the compound of formula (I) is useful as a psychotropic medicinal product, in particular for the treatment of anxiety disorders, mood disorders, delirium disorders, psychotic disorders in general, for the treatment of schizophrenia and depression, as well as for the treatment of disorders associated with the use of psychotropic substances, in particular in the case of abuse of a substance and/or dependence on a substance, including alcohol dependency and nicotine dependency.
The compound of formula (I) according to the invention can be used as medicinal product for treating neuropathies, migraine, stress, diseases of psychosomatic origin, epilepsy, locomotor disorders, in particular dyskinesias or Parkinson's disease.
The compound of formula (I) according to the 5 invention can also be used as a medicinal product in the treatment of memory disorders, cognitive disorders, in particular in the treatment of senile dementia and Alzheimer's disease, as well as in the treatment of attention disorders or vigilance disorders.
10 Furthermore, the compound of formula (I) may be useful as a neuroprotective agent, in the treatment of neurodegenerative diseases.
The compound of formula (I) according to the invention can be used as a medicinal product in the 15 treatment of appetite disorders, cravings (for sugars, carbohydrates, drugs, alcohol or any appetizing substance? and/or eating disorders, in particular as an anorexigenic agent or for the treatment of obesity or bulimia, as well as for the treatment of type II
diabetes or non-insulin-dependent diabetes.
Furthermore, the compound of formula (I) according to the invention can be used as a medicinal product in the treatment of gastrointestinal disorders, diarrheic disorders, ulcers, vomiting, urinary and bladder disorders, cardiovascular disorders, fertility disorders, inflammatory phenomena, infectious diseases and as a medicinal product for anticancer chemotherapy.
' 16 According to the present invention, the compound of formula (I) is most particularly useful for treating psychotic disorders, in particular schizophrenia; for treating appetite disorders and obesity, for treating for memory and cognitive disorders; for treating alcohol dependency or nicotine dependency, i.e. for withdrawal from alcohol and for withdrawal from tobacco.
According to one of its aspects, the present invention relates to the use of a compound of formula (I), its pharmaceutically acceptable salts and the solvates thereof for the treatment of the disorders and diseases indicated above.
According to another of its aspects, the present invention also relates to the use of the compounds of formula (I), in their native form or in radiolabelled form, as a pharmacological tool in man or animals, for detecting and labelling the CB1 receptors.
The compound according to the invention is generally administered as a dosage unit.
The said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.
Thus, according to another of its aspects, the present invention relates to pharmaceutical compositions containing, as active principle, a ' 17 compound of formula (I), one of its pharmaceutically acceptable salts or a solvate thereof.
The compound of formula (I) above and its pharmaceutically acceptable salts or solvates can be used at daily doses of from 0.01 to 100 mg per kg of body weight of the mammal to be treated, preferably at daily doses of from 0.02 to 50 mg/kg. In human beings, the dose can preferably range from 0.05 to 4000 mg per day, more particularly from 0.1 to 1000 mg per day depending on the age of the individual to be treated or the type of treatment, i.e. prophylactic or curative treatment. Although these doses are examples of average situations, it is possible to have special cases in which higher doses or lower doses are suitable, and such doses also belong to the invention. According to the usual practice, the dose which is suitable for each patient is determined by the doctor according to the method of administration and the age, weight and response of the said patient.
In the pharmaceutical compositions of the present invention for oral, sublingual, inhaled, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active principle can be administered in unit administration form, as a mixture with conventional pharmaceutical supports, to animals and to human beings. The appropriate unit forms of administration comprise oral-route forms such as tablets, gel capsules, powders, granules and oral solutions or suspensions, sublingual and buccal administration forms, aerosols, topical administration forms, implants, subcutaneous, intramuscular, intravenous, intranasal or intraocular administration forms and rectal administration forms.
In the pharmaceutical compositions of the present invention, the active principle is generally formulated in dosage units containing from 0.05 to 1000 mg, advantageously from 0.1 to 500 mg and preferably from 1 to 200 mg, of the said active principle per dosage unit for daily administrations.
When a solid composition is prepared in tablet form, a wetting agent such as sodium lauryl sulphate can be added to the micronized or non-micronized active principle, and the whole is mixed with a pharmaceutical vehicle such as silica, gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like. The tablets can be coated with sucrose, various polymers or other suitable materials or alternatively they can be treated such that they have sustained or delayed activity and such that they release a predetermined amount of active principle continuously.
A preparation in gel capsule form is obtained by mixing the active principle with a diluent such as a glycol or a glycerol ester and by incorporating the mixture obtained into soft or hard gel capsules.
A preparation in the form of a syrup or elixir can contain the active principle together with a sweetener, preferably a calorie-free sweetener, methyl paraben and propyl paraben as antiseptic agents, as well as a flavour enhancer and a suitable colorant.
The water-dispersible powders or granules can contain the active principle as a mixture with dispersants, wetting agents or suspending agents, such as polyvinylpyrrolidine, as well as with sweeteners or flavour enhancers.
For rectal administration, use is made of suppositories which are prepared with binders that melt at the rectal temperature, for example cocoa butter or polyethylene glycols.
For parenteral, intranasal or intraocular administration, aqueous suspensions, isotonic saline solutions or sterile, injectable solutions which contain pharmacologically compatible dispersants and/or solubilizing agents, for example propylene glycol or polyethylene glycol, are used.
Thus, to prepare an aqueous solution which can be injected intravenously, a co-solvent such as, for example, an alcohol, for instance ethanol or a glycol such as polyethylene glycol or propylene glycol, and a hydrophilic surfactant such as Tween~ 80, can be used. To prepare an oily solution which can be injected intramuscularly, the active principle can be dis~;olved with a triglyceride or a glycerol ester.
Creams, ointments or gels can be used for local administration.
For transdermal administration, patches in multilayer form or containing a reservoir in which the 5 active principle may be in alcoholic solution can be used.
For administration by inhalation, an aerosol is used containing, for example, sorbitan trioleate or oleic acid as well as trichlorofluoromethane, 10 dichlorofluoromethane, dichlorotetrafluoroethane or any other biologically compatible propellent gas; it is also possible to use a system containing the active principle alone or combined with an excipient, in powder form.
15 The active principle can also be formulated in the form of microcapsules or microspheres, optionally with one or more supports or additives.
The active principle can also be in the form of a complex with a cyclodextrin, for example a-, Vii- or 20 y-cyclodextrin, 2-hydroxypropyl-(3-cyclodextrin or methyl-(3-cyclodextrin.
Among the forms for sustained release which are useful in the case of chronic treatments, it is possible to use implants. These can be prepared in the form of an oily suspension or in the form of a suspension of microspheres in an isotonic medium.
The pharmaceutical compositions of the present invention can contain, along with the compound of formula (I) or one of its pharmaceutically acceptable salts or solvates, other active principles which can be useful in the treatment of the disorders or diseases indicated above.
In the present description, the following abbreviations are used:
DCM: dichloromethane LiHI~S: lithium hexamethyldisilazide TMSC1: chlorotrimethylsilane PTSA: para-toluenesulphonic acid NBS: N-bromosuccinimide MTBE: methyl tert-butyl ether RT: room temperature m.p.: melting point TLC: thin layer chromatography NMR: nuclear magnetic resonance. The NMR spectra are recorded at 200 MHz in DMSO-d6 s: singlet; d: doublet; t: triplet; q: quadruplet;
m: broad peak or multiplet; dd: doubled doublet.
Ethyl 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate A) Lithium ethyl 4-(4-bromophenyl)-3-methyl-4-oxido-2-oxobutenoate 21.6 g of LiHMDS are placed in 340 ml of anhydrous ether under nitrogen and the solution is cooled to -60°C, followed by addition of 4 g of bromopropiophenone dissolved in 150 ml of anhydrous ether. This mixture is allowed to warm to -30°C and 17.53 ml of ethyl oxalate are then added. After stirring overnight at RT, the precipitate formed is filtered off and then rinsed with ether and dried under vacuum. 21.8 g of the expected compound are obtained.
B) Ethyl 4-(4-bromophenyl)-2-[(2,4-dichlorophenyl)-hydrazono]-3-methyl-4-oxobutyrate 16.8 g of the compound prepared in the above step and 12.5 g of 2,4-dichlorophenylhydrazine hydrochloride in 150 ml of ethanol are mixed together and left stirring for 2 and a half hours. The precipitate formed is filtered off, rinsed with ethanol and then dried under vacuum. 16.24 g of the expected compound are obtained.
C) Ethyl 5-(4-bromophenyl)-1-l2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylate 16.24 g of the compound obtained in the above step are heated for 24 hours in 200 ml of acetic acid and the reaction medium is then poured into 1 litre of ice-cold water; the precipitate formed is filtered off, rinsed with water and dried under vacuum. 12.8 g of the expected compound are obtained, and this product is recrystallized from methylcyclohexane, m.p. - 133°C.
D) Ethyl 4-bromomethyl-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)pyrazole-3-carboxylate 12.8 g of the ester obtained in the above step are placed in 130 ml of carbon tetrachloride and 5.27 g of N-bromosuccinimide are added, followed by 24 mg of benzoyl peroxide. The mixture is refluxed for 4 hours and is then filtered and concentrated under vacuum. The residue is chromatographed on silica, eluting with a toluene/ethyl acetate mixture (97/3;
v/v). 7.24 g of the expected compound are obtained, m.p. - 116°C.
E) Ethyl 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate 2.26 g of CuBr are introduced as a suspension in 100 ml of ether, under argon, followed by dropwise addition at -20°C of a solution containing 20 ml of 1.6 M methyllithium in ether diluted in 20 ml of ether.
After stirring for 10 minutes at -20°C, the suspension decolorizes and then becomes clear. The resulting mixture is cooled to -78°C and 7 g of the compound prepared in the above step are added as a solution in 100 ml of ether, over 30 minutes, after which the mixture is allowed to warm to RT. After stirring for 2 hours, the mixture is hydrolysed by addition of saturated ammonium chloride solution. The resulting mixture is extracted with ether and washed with water, and then with saturated NaCl solution. This solution is dried over MgS~4 and then evaporated to dryness. The residue is chromatographed on silica, eluting with a toluene/ethyl acetate mixture (96/4; v/v). 3.7 g of the expected compound are obtained, m.p. - 108°C.
NMR: 1.05 ppm: t: 3H; 1.30 ppm: t: 3H; 2.60 ppm: q: 2H;
4.30 ppm: q: 2H; 7.15 ppm: d: 2H; 7.50-7.75 ppm: m: 5H.
5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid (II).
AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
The present invention relates to a novel pyrazole derivative, to its salts and to the solvates thereof, to a process for their preparation and to pharmaceutical compositions containing them.
Patent applications EP-A-576 357, EP-A-658 546 and WO-97/19063 describe pyrazole derivatives with affinity for cannabinoid receptors.
More particularly, patent appliction EP-A-656 354 describes N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, also known as SR 141 716, and the pharmaceutically acceptable salts thereof which have very good affinity for the central cannabinoid receptors.
Compounds similar to SR 141716 have been described in the literature, in particular N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, referred to hereinbelow as compound A, which is described by B.F. Thomas et al.
in J. Pharm. Exp. Therap., 1998, 285, 285-292.
The effects of cannabinoids are due to an interaction with specific high-affinity receptors present at the central level (Devane et al., Mol.
Pharmacol., 1988, 34, 605-613) and at the peripheral level (Nye et al., Pharmacol. and Experimental Ther., 1985, 234, 784-791 ; Kaminski et al., 1992, Mol.
Pharmacol., 42, 736-742 ; Munro et al., Nature, 1993, 365, 61-65) .
Characterization of the receptors was made possible by the development of synthetic ligands specific for cannabinoid receptors, such as the agonists WIN 55212-2 (J. Pharmacol. Exp. Ther., 1993, 264, 1352-1353) or CP 55,990 (J. Pharmacol. Exp. Ther., 1988, 247, 1046-1051). The pharmacology of the CB1 and CB2 cannabinoid receptor subtypes is outlined in Pharmacol. Ther., 1997, 79, 129-130.
A novel N-piperidino-3-pyrazolecarboxamide derivative has now been found which has very good affinity for the CB1 subtype of cannabinoid receptors (CB,_ receptors) with long-lasting action, which is useful in the therapeutic fields in which cannabinoids are known to be involved.
According to one of its aspects, the present invention relates to N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, of formula:
HSC, CO-NH- N\
~ N~ ,,~~N
CI
Br (I) ci "' 3 to its pharmaceutically acceptable salts and to the solvates thereof.
According to another of its aspects, the present invention relates to a process for preparing compound (I) above, its salts and the solvates thereof, characterized in that a functional derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid, of formula:
COOH
N~N
CI
Br (II) CI
is treated with 1-aminopiperidine, in an organic solvent and in the presence of a base; and the compound thus obtained is optionally converted into one of its salts or one of the solvates thereof.
The reaction is carried out in basic medium, for example in the presence of triethylamine in an inert solvent such as dichloromethane or tetrahydrofuran.
Functional derivatives of the acid (II) which may be used are the acid chloride, the anhydride, a mixed anhydride, a Ci-C4 alkyl ester in which the alkyl is straight or branched, an activated ester, for example the p-nitrophenyl ester, or the suitably activated free acid, for example activated with N,N-dicyclohexylcarbodiimide or with benzotriazole-N-oxotris(dimethylamino)phosphonium (BOP) hexafluorophosphate.
Thus, by means of the process according to the invention, it is possible to react the acid chloride of formula (II) obtained by reacting thionyl chloride with the acid of formula (II) in an inert solvent, such as benzene or toluene, or a chlorinated solvent (for example dichloromethane, dichloroethane or chloroform), an ether (for example tetrahydrofuran or dioxane), or an amide (for example N,N-dimethylformamide) under an inert atmosphere, at a temperature of between 0°C and the reflux point of the solvent.
One variant of the procedure consists in preparing the mixed anhydride of the acid of formula (II) by reacting ethyl chloroformate with the acid of formula (II), in the presence of a base such as triethylamine.
The acid of formula (II) can be prepared according to the reaction scheme described below, in which:
LiHMI~S = lithium hexamethyldisilazide NBS = N-bromosuccinimide.
O I) LiFBvIDS ~ ~ O' LQ
Br Br Et 2) (COzEt)2 CH COZEt ~ W
(IU) ~ ~ Cl CH
OEt ~ ~ C1 NON AcOH
Cl ~ Br / \ O N- NH CI
Br ~ ~ ~ (IV) CH3 C02Et (V) NBS
CH, MeZCuLi I) (VI) ~ KOH/McOH
HZO
(II) 5 The first step is carried out according to J. Heterocyclic. Chem., 1989, 26, 1389. In the penultimate step, the conversion of the 4-bromomethyl substituent of the pyrazole into 4-ethyl is carried out according to J. Am. Chem. Soc., 1968, 90, 5615.
The 1-aminopiperidine used is a commercial product.
'- 6 The ester of formula (VII) and the acid of formula (II) can be prepared according to another process which constitutes a further subject of the present invention.
This process is illustrated by the reaction scheme below, in which Alk represents a (C1-C6)alkyl and represents an ethyl.
O O
1 ) LiHMDS
Br / \ ~-(C~)z-CH3 OAIk Br / \ COzAIk O Et O (VIII) N
CI
O N-' NH C1 HCI
Br ~ \ CO.,AIk Et (IX) .. (1I) (VII) This process is characterized in that an alkyl ester, preferably the ethyl ester, of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid is prepared by cyclization of an alkyl ester, preferably the ethyl ester, of 3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)-hydrazono)pentanoic acid (IX).
This reaction is carried out in a protic solvent such as an alcohol, for example a C1-Ca alcohol, preferably ethanol, at a temperature of between room temperature and 80°C, preferably in reluxing ethanol.
According to the invention, the alkyl ester, preferably the ethyl ester, of 3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)hydrazono)pentanoic acid is prepared by the action of a 2,4-dichlorophenylhydrazine salt, preferably the hydrochloride, on an alkyl ester, preferably the ethyl ester, of 4-bromobenzoyl-2-oxopentanoic acid (VIII).
The reaction is carried out in a protic solvent, for example a C1-C4 alcohol, preferably ethanol.
According to the invention, the alkyl ester, preferably the ethyl ester, of 4-bromobenzoyl-2-oxopentanoic acid is prepared by the action of LiE~IDS
and then of an alkyl ester, preferably the ethyl ester, of 2-(1-imidazolyl)-2-oxoacetic acid on bromobutyrophenone.
The reaction is carried out in an organic solvent such as an aromatic solvent or an ether, preferably methyl tent-butyl ether. The first step of this reaction is carried out at low temperature, for example at a temperature between 0°C and -60°C, preferably at a temperature in the region of -20°C; the second step is carried out at a temperature of between room temperature and -20°C, preferably at room temperature.
Thus, according to Scheme 2, the preparation of an alkyl ester of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid (VII) is carried out starting with 4-bromobenzoyl-2-oxopentanoic acid (VIII) by the action of a 2,4-dichlorophenylhydrazine salt, followed by cyclization.
Bromobutyrophenone is commercially available.
The ethyl ester of 2-(1-imidazolyl)-2-oxoacetic acid is described and prepared according to J. Org. Chem., 1981, 46 (1), 211-213.
The present invention also comprises a process for preparing an alkyl ester, preferably the ethyl ester, of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid, from 4-bromobenzoyl-2-oxopentanoic acid, by the action of a 2,4-dichlorophenylhydrazine salt, preferably the hydrochloride, in a protic solvent, for example a C1-CQ alcohol, preferably ethanol. The " 9 reaction is carried out at a temperature of between room temperature and 80°C, preferably in reluxing ethanol.
The compounds of formula:
O O
Br ~ \ COZAIk (VIII) Et CI
O ~1-- NH Cl Br ~ \ CY 'COZAIk (IX) IEt in which Alk represents a (C1-C6)alkyl are novel and form part of the invention. Preferably, Alk represents an ethyl.
The compound of formula (I) obtained by the process according to the invention is isolated, in the form of the free base or of a salt or solvate, according to the conventional techniques.
The pharmaceutically acceptable salts of the compound of formula (I) comprise the addition salts with acids, such as the hydrochloride, the hydrobromide, the sulphate, the hydrogen sulphate, the dihydrogen phosphate, the methanesulphonate, the methyl sulphate, the oxalate, the maleate, the fumarate, the 1~
2-naphthalenesulphonate, the glyconate, the gluconate, the citrate, the isethionate, the para-toluenesulphonate or the succinate.
The compound of formula (I) can be isolated in the form of one of its salts, for example the hydrochloride or the oxalate; in this case, the free base can be prepared by neutralizing the said salt with an inorganic or organic base, such as sodium hydroxide or ammonium hydroxide, triethylamine or an alkali metal carbonate or bicarbonate such as sodium or potassium carbonate or bicarbonate, and converted into another salt such as the methanesulphonate, fumarate or 2-naphthalenesulphonate.
When the compound of formula (I) is obtained in the form of the free base, the salification is carried out by treatment with the acid chosen in an organic solvent. By treating the free base, dissolved, for example, in an ether such as diethyl ether or in acetone, with a solution of the acid in the same solvent, the corresponding salt is obtained and is then isolated according to the conventional techniques.
The compounds of formula (I) have very good in vitro affinity for the CB1 cannabinoid receptors, under the experimental conditions described by Devane et al., Mol. Pharmacol., 1988, 34, 605-613.
Thus, the compound according to the invention has very strong affinity for human CB1 cannabinoid receptors (Ki = 5.4 nM) which compares favourably with that of SR 141716 for the same receptors, determined under the same conditions (Ki = 34 nM).
The compound according to the invention was also compared with N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, (compound A). The affinity of this compound for human CB1 cannabinoid receptors, measured under the same conditions, is reflected by a Ki value of 8 nM.
Moreover, the duration of occupation of the Cel receptors present in the brain by the 3 compounds below was compared:
- the compound of formula (I) according to the invention, - SR 141716, - compound A.
The study was performed in vivo in mice, after oral administration of each of the compounds at a dose of 10 mg/kg, according to the technique described in M. Rinaldi-Carmona et al., Life Sciences, 1995, 56, 1941-1947. The results obtained are collated in the table below.
mTnr c 'f $ of occupation of the receptors 1 hour 24 hours Compound of 82~ 44~
formula (I) SR 141716 69~ 4~
Compound A 89~ 4$
Surprisingly, it is observed that the compound of formula (I) according to the invention is the only compound which shows appreciable occupation (44~) 24 hours after its administration.
Moreover, the antagonist nature of the compound of formula (I) was demonstrated by the results obtained in models of adenylate-cyclase inhibition as described in M. Rinaldi-Carmona et al., J. Pharmacol.
Exp. Ther., 1996, 278, 871-878.
More particularly, the compound of the present invention, in its native form or in the form of one of its pharmaceutically acceptable salts, is a powerful and selective antagonist of the CB1 cannabinoid receptors.
The antagonist nature of the compound according to the invention, as well as its good penetration into the central nervous system, are confirmed by the results obtained in the model of antagonism of the hypothermia induced with a cannabinoid receptor agonist. Thus, the compound of formula (I) according to the invention antagonizes the hypothermia induced with WIN 55212-2 in mice, with an oral EDSO of 0.3 mg/kg in the test described by Pertwee R.G. et al. in Marijuana, 84, Ed. Harvey, D.Y.
Oxford IRL Press, 1985, 263-277. In this test, the activity and the duration of action of 3 compounds were compared. The results obtained are collated in the table below:
Antagonism of the hypothermia induced Duration of action oral EDSOoral 24 h dose Compound of formula 0.3 mg/kg1 mg/kg active (I) SR 141716 0.4 mg/kg1 mg/kg not active 10 mg/kg active Compound A 0.3 mg/kg1 mg/kg not active 10 mg/kg active It is found that the compound of the present invention has an EDSo which is comparable with those of the compounds of the prior art, but its duration of action is markedly longer.
Thus, whereas 24 hours after their administration, SR 141716 and compound A are only active at a dose of 10 mg/kg/p.o., the compound of formula (I) according to the invention is active 24 hours after its administration, at a dose 10 times lower (1 mg/kg/p.o.).
The long-lasting action of the compound of formula (I) according to the invention is particularly noteworthy and represents an important advantage for its use as a medicinal product.
The toxicity of compounds (I) is compatible with their use as medicinal products.
According to another of its aspects, the present invention relates to the use of a compound of formula (I), or one of the pharmaceutically acceptable salts or solvates thereof, for the preparation of medicinal products intended for treating diseases involving the CB1 cannabinoid receptors.
For example, and in a non-limiting manner, the compound of formula (I) is useful as a psychotropic medicinal product, in particular for the treatment of anxiety disorders, mood disorders, delirium disorders, psychotic disorders in general, for the treatment of schizophrenia and depression, as well as for the treatment of disorders associated with the use of psychotropic substances, in particular in the case of abuse of a substance and/or dependence on a substance, including alcohol dependency and nicotine dependency.
The compound of formula (I) according to the invention can be used as medicinal product for treating neuropathies, migraine, stress, diseases of psychosomatic origin, epilepsy, locomotor disorders, in particular dyskinesias or Parkinson's disease.
The compound of formula (I) according to the 5 invention can also be used as a medicinal product in the treatment of memory disorders, cognitive disorders, in particular in the treatment of senile dementia and Alzheimer's disease, as well as in the treatment of attention disorders or vigilance disorders.
10 Furthermore, the compound of formula (I) may be useful as a neuroprotective agent, in the treatment of neurodegenerative diseases.
The compound of formula (I) according to the invention can be used as a medicinal product in the 15 treatment of appetite disorders, cravings (for sugars, carbohydrates, drugs, alcohol or any appetizing substance? and/or eating disorders, in particular as an anorexigenic agent or for the treatment of obesity or bulimia, as well as for the treatment of type II
diabetes or non-insulin-dependent diabetes.
Furthermore, the compound of formula (I) according to the invention can be used as a medicinal product in the treatment of gastrointestinal disorders, diarrheic disorders, ulcers, vomiting, urinary and bladder disorders, cardiovascular disorders, fertility disorders, inflammatory phenomena, infectious diseases and as a medicinal product for anticancer chemotherapy.
' 16 According to the present invention, the compound of formula (I) is most particularly useful for treating psychotic disorders, in particular schizophrenia; for treating appetite disorders and obesity, for treating for memory and cognitive disorders; for treating alcohol dependency or nicotine dependency, i.e. for withdrawal from alcohol and for withdrawal from tobacco.
According to one of its aspects, the present invention relates to the use of a compound of formula (I), its pharmaceutically acceptable salts and the solvates thereof for the treatment of the disorders and diseases indicated above.
According to another of its aspects, the present invention also relates to the use of the compounds of formula (I), in their native form or in radiolabelled form, as a pharmacological tool in man or animals, for detecting and labelling the CB1 receptors.
The compound according to the invention is generally administered as a dosage unit.
The said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.
Thus, according to another of its aspects, the present invention relates to pharmaceutical compositions containing, as active principle, a ' 17 compound of formula (I), one of its pharmaceutically acceptable salts or a solvate thereof.
The compound of formula (I) above and its pharmaceutically acceptable salts or solvates can be used at daily doses of from 0.01 to 100 mg per kg of body weight of the mammal to be treated, preferably at daily doses of from 0.02 to 50 mg/kg. In human beings, the dose can preferably range from 0.05 to 4000 mg per day, more particularly from 0.1 to 1000 mg per day depending on the age of the individual to be treated or the type of treatment, i.e. prophylactic or curative treatment. Although these doses are examples of average situations, it is possible to have special cases in which higher doses or lower doses are suitable, and such doses also belong to the invention. According to the usual practice, the dose which is suitable for each patient is determined by the doctor according to the method of administration and the age, weight and response of the said patient.
In the pharmaceutical compositions of the present invention for oral, sublingual, inhaled, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active principle can be administered in unit administration form, as a mixture with conventional pharmaceutical supports, to animals and to human beings. The appropriate unit forms of administration comprise oral-route forms such as tablets, gel capsules, powders, granules and oral solutions or suspensions, sublingual and buccal administration forms, aerosols, topical administration forms, implants, subcutaneous, intramuscular, intravenous, intranasal or intraocular administration forms and rectal administration forms.
In the pharmaceutical compositions of the present invention, the active principle is generally formulated in dosage units containing from 0.05 to 1000 mg, advantageously from 0.1 to 500 mg and preferably from 1 to 200 mg, of the said active principle per dosage unit for daily administrations.
When a solid composition is prepared in tablet form, a wetting agent such as sodium lauryl sulphate can be added to the micronized or non-micronized active principle, and the whole is mixed with a pharmaceutical vehicle such as silica, gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like. The tablets can be coated with sucrose, various polymers or other suitable materials or alternatively they can be treated such that they have sustained or delayed activity and such that they release a predetermined amount of active principle continuously.
A preparation in gel capsule form is obtained by mixing the active principle with a diluent such as a glycol or a glycerol ester and by incorporating the mixture obtained into soft or hard gel capsules.
A preparation in the form of a syrup or elixir can contain the active principle together with a sweetener, preferably a calorie-free sweetener, methyl paraben and propyl paraben as antiseptic agents, as well as a flavour enhancer and a suitable colorant.
The water-dispersible powders or granules can contain the active principle as a mixture with dispersants, wetting agents or suspending agents, such as polyvinylpyrrolidine, as well as with sweeteners or flavour enhancers.
For rectal administration, use is made of suppositories which are prepared with binders that melt at the rectal temperature, for example cocoa butter or polyethylene glycols.
For parenteral, intranasal or intraocular administration, aqueous suspensions, isotonic saline solutions or sterile, injectable solutions which contain pharmacologically compatible dispersants and/or solubilizing agents, for example propylene glycol or polyethylene glycol, are used.
Thus, to prepare an aqueous solution which can be injected intravenously, a co-solvent such as, for example, an alcohol, for instance ethanol or a glycol such as polyethylene glycol or propylene glycol, and a hydrophilic surfactant such as Tween~ 80, can be used. To prepare an oily solution which can be injected intramuscularly, the active principle can be dis~;olved with a triglyceride or a glycerol ester.
Creams, ointments or gels can be used for local administration.
For transdermal administration, patches in multilayer form or containing a reservoir in which the 5 active principle may be in alcoholic solution can be used.
For administration by inhalation, an aerosol is used containing, for example, sorbitan trioleate or oleic acid as well as trichlorofluoromethane, 10 dichlorofluoromethane, dichlorotetrafluoroethane or any other biologically compatible propellent gas; it is also possible to use a system containing the active principle alone or combined with an excipient, in powder form.
15 The active principle can also be formulated in the form of microcapsules or microspheres, optionally with one or more supports or additives.
The active principle can also be in the form of a complex with a cyclodextrin, for example a-, Vii- or 20 y-cyclodextrin, 2-hydroxypropyl-(3-cyclodextrin or methyl-(3-cyclodextrin.
Among the forms for sustained release which are useful in the case of chronic treatments, it is possible to use implants. These can be prepared in the form of an oily suspension or in the form of a suspension of microspheres in an isotonic medium.
The pharmaceutical compositions of the present invention can contain, along with the compound of formula (I) or one of its pharmaceutically acceptable salts or solvates, other active principles which can be useful in the treatment of the disorders or diseases indicated above.
In the present description, the following abbreviations are used:
DCM: dichloromethane LiHI~S: lithium hexamethyldisilazide TMSC1: chlorotrimethylsilane PTSA: para-toluenesulphonic acid NBS: N-bromosuccinimide MTBE: methyl tert-butyl ether RT: room temperature m.p.: melting point TLC: thin layer chromatography NMR: nuclear magnetic resonance. The NMR spectra are recorded at 200 MHz in DMSO-d6 s: singlet; d: doublet; t: triplet; q: quadruplet;
m: broad peak or multiplet; dd: doubled doublet.
Ethyl 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate A) Lithium ethyl 4-(4-bromophenyl)-3-methyl-4-oxido-2-oxobutenoate 21.6 g of LiHMDS are placed in 340 ml of anhydrous ether under nitrogen and the solution is cooled to -60°C, followed by addition of 4 g of bromopropiophenone dissolved in 150 ml of anhydrous ether. This mixture is allowed to warm to -30°C and 17.53 ml of ethyl oxalate are then added. After stirring overnight at RT, the precipitate formed is filtered off and then rinsed with ether and dried under vacuum. 21.8 g of the expected compound are obtained.
B) Ethyl 4-(4-bromophenyl)-2-[(2,4-dichlorophenyl)-hydrazono]-3-methyl-4-oxobutyrate 16.8 g of the compound prepared in the above step and 12.5 g of 2,4-dichlorophenylhydrazine hydrochloride in 150 ml of ethanol are mixed together and left stirring for 2 and a half hours. The precipitate formed is filtered off, rinsed with ethanol and then dried under vacuum. 16.24 g of the expected compound are obtained.
C) Ethyl 5-(4-bromophenyl)-1-l2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylate 16.24 g of the compound obtained in the above step are heated for 24 hours in 200 ml of acetic acid and the reaction medium is then poured into 1 litre of ice-cold water; the precipitate formed is filtered off, rinsed with water and dried under vacuum. 12.8 g of the expected compound are obtained, and this product is recrystallized from methylcyclohexane, m.p. - 133°C.
D) Ethyl 4-bromomethyl-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)pyrazole-3-carboxylate 12.8 g of the ester obtained in the above step are placed in 130 ml of carbon tetrachloride and 5.27 g of N-bromosuccinimide are added, followed by 24 mg of benzoyl peroxide. The mixture is refluxed for 4 hours and is then filtered and concentrated under vacuum. The residue is chromatographed on silica, eluting with a toluene/ethyl acetate mixture (97/3;
v/v). 7.24 g of the expected compound are obtained, m.p. - 116°C.
E) Ethyl 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate 2.26 g of CuBr are introduced as a suspension in 100 ml of ether, under argon, followed by dropwise addition at -20°C of a solution containing 20 ml of 1.6 M methyllithium in ether diluted in 20 ml of ether.
After stirring for 10 minutes at -20°C, the suspension decolorizes and then becomes clear. The resulting mixture is cooled to -78°C and 7 g of the compound prepared in the above step are added as a solution in 100 ml of ether, over 30 minutes, after which the mixture is allowed to warm to RT. After stirring for 2 hours, the mixture is hydrolysed by addition of saturated ammonium chloride solution. The resulting mixture is extracted with ether and washed with water, and then with saturated NaCl solution. This solution is dried over MgS~4 and then evaporated to dryness. The residue is chromatographed on silica, eluting with a toluene/ethyl acetate mixture (96/4; v/v). 3.7 g of the expected compound are obtained, m.p. - 108°C.
NMR: 1.05 ppm: t: 3H; 1.30 ppm: t: 3H; 2.60 ppm: q: 2H;
4.30 ppm: q: 2H; 7.15 ppm: d: 2H; 7.50-7.75 ppm: m: 5H.
5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid (II).
3.6 g of the ester obtained in Preparation 1 are placed in 54 ml of MeOH and a solution containing 1.08 g of KOH in 6.85 ml of water is added. The reaction medium is refluxed for 3 hours and then concentrated under vacuum. The residue is taken up in ice-cold water, acidified to pH = 1 with 1 N HC1 and then extracted with DCM. 3.3 g of the expected compound are obtained, m.p. - 218°C.
NMR: 1.10 ppm: t: 3H; 2.70 ppm: q: 2H; 7.25 ppm: d: 2H;
7.60-7.85 ppm: m: 5H.
Ethyl 3-(4-bromobenzoyl)-2-oxopentanoate A solution of 247 g of 4-bromobutyrophenone in 1500 ml of MTBE is added to a solution of 210 g of LiHMDS in 2500 ml of MTBE, while keeping the temperature at -20°C. After stirring for 3 hours at this temperature, 210 g of ethyl 2-(1-imidazolyl)-2-oxoacetate in 1000 ml of MTBE are added over 1 hour, at 10°C, and the mixture is left stirring for 18 hours at room temperature. The lithium salt formed is filtered off and then suspended in 800 ml of MTBE.
800 ml of 6 N hydrochloric acid are added to the suspension. After separation of the phases by settling, the ether phase is washed 4 times with 1000 ml of water and then concentrated under reduced pressure. The 5 expected compound is isolated (263 g). From the NMR
analysis, it is a mixture containing 8$ of the 4-bromobutyrophenone starting material.
NMR: 0.86 ppm: t: 3H; 1.10 ppm: t: 3H; 1.83 ppm: mt:
2H; 4.15 ppm: q: 2H; 5.19 ppm: t: 1H; 7.70 ppm: d: 2H;
10 7.98 ppm: d: 2H.
Ethyl 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate 15 A) Ethyl 3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)-hydrazono)pentanoate A suspension of 155 g of 2,4-dichlorophenylhydrazine hydrochloride in 1200 ml of ethanol is prepared and 263 g of the compound of 20 Preparation 3 in 1000 ml of ethanol are added at room temperature.
A small portion of the intermediate formed can be isolated by filtration and characterized.
NMR: 0.92 ppm: t: 3H; 1.04 ppm: t: 3H; 1.89 ppm: mt:
25 2H; 4.16 ppm: q: 2H; 4.76 ppm: t: 1H; 7.42 ppm: mt: 2H;
7.60 ppm: s: 1H; 7.75 ppm: d: 2H; 7.93 ppm: d: 2H;
12.31 ppm: s: 1H.
B) Ethyl 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate The suspension obtained is refluxed for 4 hours and then left stirring for 18 hours at room temperature. The product formed is filtered off and then dried under vacuum at 50°C to give the expected compound (247 g), m.p. - 108°C.
NMR: 1.07 ppm: t: 3H; 1.28 ppm: t: 3H; 2.58 ppm: q: 2H;
4.32 ppm: q: 2H; 7.16 ppm: d: 2H; 7.53 ppm: dd: 1H;
7.59 ppm: d: 2H; 7.73 ppm: d + small d: 2H.
EXAMPLE 1N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide A) 5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid chloride 3.2 g of the acid obtained in the above step are placed in suspension in 32 ml of toluene, 1.6 ml of thionyl chloride are added and the mixture is then refluxed for 3 hours. The reaction medium is concentrated under vacuum and then taken up in toluene.
The operation is repeated several times. 3.3 g of the expected compound are obtained.
B) N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-4-ethylpyrazole-3-carboxamide A solution of 0.23 ml of N-aminopiperidine and 0.29 ml of triethylamine in 20 ml of.DCM is prepared, under nitrogen, and is cooled to a temperature of between 0°C and 5°C. 0.8 g of the acid chloride obtained in the above step in 20 ml of DCM is added. After leaving overnight at RT, the resulting mixture is poured onto ice-cold water and the phases are separated by settling. The organic phase is extracted with DCM and then washed with water, with 5$
Na2C03 solution and with saturated NaCl solution. The resulting solution is evaporated to dryness and the residue is then chromatographed on silica, eluting with a toluene/EtOAc mixture (80/20; v/v). 0.52 g of the expected compound is obtained, m.p. - 113°C.
NMR: 1.05 ppm: t: 3H; 1.25-1.65 ppm: m: 6H; 2.55 ppm:
q: 2H; 2.80 ppm: m: 4H; 7.15 ppm: d: 2H; 7.50-7.80 ppm:
m: 5H; 9.10 ppm: s: 1H.
N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide A) 5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid chloride A mixture containing 97 g of thionyl chloride and 118 g of the compound of Preparation 4 in 1200 ml of toluene is prepared and is heated gradually to reflux and is then maintained at reflux for 3 hours.
The reaction medium is concentrated.
B) N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-4-ethylpyrazole-3-carboxamide The acid chloride formed is taken up in 380 ml of methylcyclohexane and 2.8 g of triethylamine in 218 ml of THF are introduced. The mixture is kept at 50°C.
A solution of 30 g of N-aminopiperidine and 28 g of triethylamine in 34 ml of methylcyclohexane is prepared and cooled to 10°C, and the mixture containing the acid chloride is added slowly. After stirring for 2 hours at 10°C, the product formed is filtered off, taken up in 2000 ml of DCM and washed twice with 2000 ml of water. The product is recrystallized from 4500 ml of methylcyclohexane and then filtered off and dried. 125 g of the expected compound are obtained.
NMR: 1.10 ppm: t: 3H; 2.70 ppm: q: 2H; 7.25 ppm: d: 2H;
7.60-7.85 ppm: m: 5H.
Ethyl 3-(4-bromobenzoyl)-2-oxopentanoate A solution of 247 g of 4-bromobutyrophenone in 1500 ml of MTBE is added to a solution of 210 g of LiHMDS in 2500 ml of MTBE, while keeping the temperature at -20°C. After stirring for 3 hours at this temperature, 210 g of ethyl 2-(1-imidazolyl)-2-oxoacetate in 1000 ml of MTBE are added over 1 hour, at 10°C, and the mixture is left stirring for 18 hours at room temperature. The lithium salt formed is filtered off and then suspended in 800 ml of MTBE.
800 ml of 6 N hydrochloric acid are added to the suspension. After separation of the phases by settling, the ether phase is washed 4 times with 1000 ml of water and then concentrated under reduced pressure. The 5 expected compound is isolated (263 g). From the NMR
analysis, it is a mixture containing 8$ of the 4-bromobutyrophenone starting material.
NMR: 0.86 ppm: t: 3H; 1.10 ppm: t: 3H; 1.83 ppm: mt:
2H; 4.15 ppm: q: 2H; 5.19 ppm: t: 1H; 7.70 ppm: d: 2H;
10 7.98 ppm: d: 2H.
Ethyl 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate 15 A) Ethyl 3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)-hydrazono)pentanoate A suspension of 155 g of 2,4-dichlorophenylhydrazine hydrochloride in 1200 ml of ethanol is prepared and 263 g of the compound of 20 Preparation 3 in 1000 ml of ethanol are added at room temperature.
A small portion of the intermediate formed can be isolated by filtration and characterized.
NMR: 0.92 ppm: t: 3H; 1.04 ppm: t: 3H; 1.89 ppm: mt:
25 2H; 4.16 ppm: q: 2H; 4.76 ppm: t: 1H; 7.42 ppm: mt: 2H;
7.60 ppm: s: 1H; 7.75 ppm: d: 2H; 7.93 ppm: d: 2H;
12.31 ppm: s: 1H.
B) Ethyl 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate The suspension obtained is refluxed for 4 hours and then left stirring for 18 hours at room temperature. The product formed is filtered off and then dried under vacuum at 50°C to give the expected compound (247 g), m.p. - 108°C.
NMR: 1.07 ppm: t: 3H; 1.28 ppm: t: 3H; 2.58 ppm: q: 2H;
4.32 ppm: q: 2H; 7.16 ppm: d: 2H; 7.53 ppm: dd: 1H;
7.59 ppm: d: 2H; 7.73 ppm: d + small d: 2H.
EXAMPLE 1N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide A) 5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid chloride 3.2 g of the acid obtained in the above step are placed in suspension in 32 ml of toluene, 1.6 ml of thionyl chloride are added and the mixture is then refluxed for 3 hours. The reaction medium is concentrated under vacuum and then taken up in toluene.
The operation is repeated several times. 3.3 g of the expected compound are obtained.
B) N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-4-ethylpyrazole-3-carboxamide A solution of 0.23 ml of N-aminopiperidine and 0.29 ml of triethylamine in 20 ml of.DCM is prepared, under nitrogen, and is cooled to a temperature of between 0°C and 5°C. 0.8 g of the acid chloride obtained in the above step in 20 ml of DCM is added. After leaving overnight at RT, the resulting mixture is poured onto ice-cold water and the phases are separated by settling. The organic phase is extracted with DCM and then washed with water, with 5$
Na2C03 solution and with saturated NaCl solution. The resulting solution is evaporated to dryness and the residue is then chromatographed on silica, eluting with a toluene/EtOAc mixture (80/20; v/v). 0.52 g of the expected compound is obtained, m.p. - 113°C.
NMR: 1.05 ppm: t: 3H; 1.25-1.65 ppm: m: 6H; 2.55 ppm:
q: 2H; 2.80 ppm: m: 4H; 7.15 ppm: d: 2H; 7.50-7.80 ppm:
m: 5H; 9.10 ppm: s: 1H.
N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide A) 5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid chloride A mixture containing 97 g of thionyl chloride and 118 g of the compound of Preparation 4 in 1200 ml of toluene is prepared and is heated gradually to reflux and is then maintained at reflux for 3 hours.
The reaction medium is concentrated.
B) N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-4-ethylpyrazole-3-carboxamide The acid chloride formed is taken up in 380 ml of methylcyclohexane and 2.8 g of triethylamine in 218 ml of THF are introduced. The mixture is kept at 50°C.
A solution of 30 g of N-aminopiperidine and 28 g of triethylamine in 34 ml of methylcyclohexane is prepared and cooled to 10°C, and the mixture containing the acid chloride is added slowly. After stirring for 2 hours at 10°C, the product formed is filtered off, taken up in 2000 ml of DCM and washed twice with 2000 ml of water. The product is recrystallized from 4500 ml of methylcyclohexane and then filtered off and dried. 125 g of the expected compound are obtained.
Claims (7)
1. N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, of formula:
its pharmaceutically acceptable salts and the solvates thereof.
its pharmaceutically acceptable salts and the solvates thereof.
2. Process for preparing N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, its salts and solvates thereof, comprising the steps of:
(i) reacting bromobutyrophenone with LiHMDS in an inorganic solvent at a temperature between 0°C and 60°C and then with 2-(1-imidazolyl)-2-oxoacetic acid at a temperature between -20°C and room temperature to prepare a C1-C4-alkyl ester of 4-bromobenzoyl-2-oxopentanoic acid;
(ii) reacting the C1-C4-alkyl ester of 4-bromobenzoyl-2-oxopentanoic acid with 2,4-dichlorophenyl-hydrazine salt in a protic solvent to prepare a C1-C4-alkyl ester of 3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)hydrazono)pentanoic acid;
(iii) cyclizing the C1-C4-alkyl ester of 3-(4-bromobenzoyl)-2-(2-(2,4-dicholorphenyl)-hydrazono)pentanoic acid to prepare a C1-C4-alkyl ester of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid of formula (II) (iv) treating 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine, in an organic solvent and in the presence of a base; and the compound thus obtained is optionally converted into one of its salts or one of the solvates thereof to prepare N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, its salts and the solvates thereof.
(i) reacting bromobutyrophenone with LiHMDS in an inorganic solvent at a temperature between 0°C and 60°C and then with 2-(1-imidazolyl)-2-oxoacetic acid at a temperature between -20°C and room temperature to prepare a C1-C4-alkyl ester of 4-bromobenzoyl-2-oxopentanoic acid;
(ii) reacting the C1-C4-alkyl ester of 4-bromobenzoyl-2-oxopentanoic acid with 2,4-dichlorophenyl-hydrazine salt in a protic solvent to prepare a C1-C4-alkyl ester of 3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)hydrazono)pentanoic acid;
(iii) cyclizing the C1-C4-alkyl ester of 3-(4-bromobenzoyl)-2-(2-(2,4-dicholorphenyl)-hydrazono)pentanoic acid to prepare a C1-C4-alkyl ester of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid of formula (II) (iv) treating 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine, in an organic solvent and in the presence of a base; and the compound thus obtained is optionally converted into one of its salts or one of the solvates thereof to prepare N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, its salts and the solvates thereof.
3. Process for preparing N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, its salts and solvates thereof, comprising the steps of:
(i) reacting 4-bromobenzoyl-2-oxopentanoic acid with a 2,4-dicholorphenylhydrazine salt in a protic solvent at a temperature between room temperature and 80°C
to prepare a C1-C4-alkyl ester of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid of formula (II) (ii) treating 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine, in an organic solvent and in the presence of a base; and the compound thus obtained is optionally converted into one of its salts or one of the solvates thereof to prepare N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, its salts and the solvates thereof.
(i) reacting 4-bromobenzoyl-2-oxopentanoic acid with a 2,4-dicholorphenylhydrazine salt in a protic solvent at a temperature between room temperature and 80°C
to prepare a C1-C4-alkyl ester of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid of formula (II) (ii) treating 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine, in an organic solvent and in the presence of a base; and the compound thus obtained is optionally converted into one of its salts or one of the solvates thereof to prepare N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, its salts and the solvates thereof.
4. Pharmaceutical composition containing, as active principle, a compound according to Claim 1 in admixture with a pharmaceutically acceptable carrier or diluent.
5. Pharmaceutical composition according to Claim 4 containing from 0.1 to 1000 mg of active principle, in unit dosage form, in which the active principle is mixed with at least one pharmaceutical excipient.
6. Use of a compound according to Claim 1 for the preparation of medicinal products intended for treating diseases involving the CB1 cannabinoid receptors.
7. Use of a compound according to Claim 6 for the treatment of psychotic disorders, for the treatment of appetite disorders and obesity, for the treatment of memory and cognitive disorders; for the treatment of alcohol dependency and for withdrawal from tobacco.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9901201A FR2789078B3 (en) | 1999-02-01 | 1999-02-01 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR99/01201 | 1999-02-01 | ||
| FR9910166A FR2789079B3 (en) | 1999-02-01 | 1999-08-02 | PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| FR99/10166 | 1999-08-02 | ||
| PCT/FR2000/000194 WO2000046209A1 (en) | 1999-02-01 | 2000-01-28 | Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2358885A1 CA2358885A1 (en) | 2000-08-10 |
| CA2358885C true CA2358885C (en) | 2007-04-17 |
Family
ID=26234792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002358885A Expired - Fee Related CA2358885C (en) | 1999-02-01 | 2000-01-28 | Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US6432984B1 (en) |
| EP (1) | EP1150961B1 (en) |
| JP (1) | JP3794925B2 (en) |
| KR (1) | KR100425405B1 (en) |
| CN (1) | CN1146544C (en) |
| AR (1) | AR020558A1 (en) |
| AT (1) | ATE252562T1 (en) |
| AU (1) | AU754771B2 (en) |
| BG (1) | BG65193B1 (en) |
| BR (1) | BR0007895A (en) |
| CA (1) | CA2358885C (en) |
| CO (1) | CO5160257A1 (en) |
| CZ (1) | CZ297667B6 (en) |
| DE (1) | DE60006070T2 (en) |
| DK (1) | DK1150961T3 (en) |
| EE (1) | EE04343B1 (en) |
| ES (1) | ES2208267T3 (en) |
| FR (1) | FR2789079B3 (en) |
| HK (1) | HK1039329A1 (en) |
| HR (1) | HRP20010564B1 (en) |
| HU (1) | HUP0201278A3 (en) |
| ID (1) | ID29534A (en) |
| IL (2) | IL144198A0 (en) |
| IS (1) | IS2448B (en) |
| ME (2) | ME00052B (en) |
| NO (1) | NO319824B1 (en) |
| NZ (1) | NZ512886A (en) |
| PE (1) | PE20001493A1 (en) |
| PL (1) | PL198422B1 (en) |
| PT (1) | PT1150961E (en) |
| RS (1) | RS50209B (en) |
| RU (1) | RU2216542C2 (en) |
| SK (1) | SK284203B6 (en) |
| TR (1) | TR200102054T2 (en) |
| TW (1) | TW581764B (en) |
| UA (1) | UA66900C2 (en) |
| WO (1) | WO2000046209A1 (en) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2789079B3 (en) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| FR2799124B1 (en) | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | USE OF ANTAGONISTS OF CENTRAL CANNABINOID RECEPTORS FOR THE PREPARATION OF DRUGS |
| US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| FR2804604B1 (en) * | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | USE OF A CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF USEFUL DRUGS TO FACILITATE THE STOPPAGE OF TOBACCO CONSUMPTION |
| FR2809621B1 (en) * | 2000-05-12 | 2002-09-06 | Sanofi Synthelabo | USE OF A CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF MEDICINES SUITABLE AS ANTIDIARRHOISTS |
| US20020091114A1 (en) | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
| BR0211705A (en) * | 2001-08-06 | 2004-09-28 | Astrazeneca Ab | A process for preparing a stable dispersion of solid particles in an aqueous medium, a stable dispersion of aqueous solid particles, a pharmaceutical composition, a method for inhibiting ostwald ripening in a dispersion of substantially water-insoluble solid particles in an aqueous medium, and , use of an inhibitor |
| WO2003026647A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| US7109216B2 (en) | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| CN1529595A (en) * | 2001-09-21 | 2004-09-15 | ������ҩ������˾ | 4,5-hydro-1H-pyrazole derivative having protent CB1-antagonistic |
| TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| WO2003075917A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| AR038966A1 (en) * | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | DERIVATIVES OF TIAZOL THAT HAVE ANTAGONIST, AGONIST OR PARTIAL AGONIST ACTIVITY OF CB1 |
| WO2003082191A2 (en) * | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| FR2837706A1 (en) * | 2002-03-28 | 2003-10-03 | Sanofi Synthelabo | USE OF A CB1 CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF MEDICINES USEFUL FOR THE TREATMENT OF SEXUAL DYSFUNCTION AND / OR IMPROVING SEXUAL PERFORMANCE |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| US6972291B2 (en) * | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
| GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| KR100741231B1 (en) * | 2002-07-29 | 2007-07-19 | 에프. 호프만-라 로슈 아게 | Novel benzodioxoles |
| US7319110B2 (en) * | 2002-09-19 | 2008-01-15 | Solvay Pharmaceuticals B.V. | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity |
| SE0203070D0 (en) | 2002-10-16 | 2002-10-16 | Astrazeneca Ab | Novel compounds |
| AU2003267728A1 (en) * | 2002-10-18 | 2004-05-04 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| FR2849032B1 (en) * | 2002-12-23 | 2006-04-28 | Sanofi Synthelabo | 5- (4-BROMOPHENYL) -1- (2,4-DICHLOROPHENYL) -4-ETHYL-N - (PIPERIDIN-1-YL) -1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVE, ITS PREPARATION, ITS THERAPEUTIC APPLICATION |
| GB0230087D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| DE60322114D1 (en) * | 2003-01-02 | 2008-08-21 | Hoffmann La Roche | PYRROLYL THIAZOLE AND THEIR USE AS INVERSE AGONISTS OF THE CB 1 RECEPTOR |
| CN101012193A (en) * | 2003-01-02 | 2007-08-08 | 霍夫曼-拉罗奇有限公司 | Novel CB 1 receptour inverse agonists |
| GB0302672D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| WO2004078261A1 (en) * | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| BRPI0410289A (en) * | 2003-05-07 | 2006-05-16 | Pfizer Prod Inc | cannabinoid receptor ligands and their uses |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| SE0301701D0 (en) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0301699D0 (en) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0301698D0 (en) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| AU2004247615B2 (en) * | 2003-06-18 | 2008-02-21 | Astrazeneca Ab | 2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators |
| GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| MXPA05013733A (en) | 2003-06-20 | 2006-03-08 | Hoffmann La Roche | 2-aminobenzothiazoles as cb1 receptor inverse agonists. |
| US7517900B2 (en) * | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| FR2861303A1 (en) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks, dyslipidemia and liver disease associated with obesity |
| FR2861301B1 (en) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | USE OF THE PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME. |
| FR2861302A1 (en) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks and dyslipidemia associated with obesity |
| FR2861300B1 (en) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME |
| CA2547804A1 (en) | 2003-12-08 | 2005-06-30 | F. Hoffmann-La Roche Ag | Novel thiazole derivatives |
| BRPI0507120A (en) | 2004-01-28 | 2007-06-19 | Hoffmann La Roche | compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and their use |
| US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| FR2866340B1 (en) * | 2004-02-13 | 2006-11-24 | Sanofi Synthelabo | OXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS. |
| RU2375349C2 (en) * | 2004-02-20 | 2009-12-10 | Астразенека Аб | Derivatives of 3-substituted 1,5-diphenylpyrazole effective as cb1 modulators |
| EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| FR2867685B1 (en) * | 2004-03-17 | 2008-05-23 | Sanofi Synthelabo | USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF DRUGS USEFUL IN THE PREVENTION AND TREATMENT OF CHRONIC BRONCHITIS AND OBSTRUCTIVE CHRONIC BRONCHO PNEUMOPATHY |
| MXPA06012813A (en) | 2004-05-10 | 2007-01-26 | Hoffmann La Roche | Pyrrole or imidazole amides for treating obesity. |
| ITMI20041032A1 (en) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | PHARMACEUTICAL COMPOSITES |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| EP2343302A1 (en) | 2004-07-12 | 2011-07-13 | Cadila Healthcare Limited | Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
| US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| CA2581596A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
| CN101048382B (en) | 2004-10-27 | 2010-05-05 | 霍夫曼-拉罗奇有限公司 | New indole or benzimidazole derivatives |
| ATE486067T1 (en) | 2004-11-09 | 2010-11-15 | Hoffmann La Roche | DIBENZOSUBERONE DERIVATIVES |
| KR101351209B1 (en) | 2004-12-03 | 2014-02-06 | 머크 샤프 앤드 돔 코포레이션 | Substituted piperazines as CB1 antagonists |
| WO2006067443A1 (en) * | 2004-12-23 | 2006-06-29 | Astrazeneca Ab | Therapeutic agents |
| FR2880023B1 (en) | 2004-12-23 | 2007-02-23 | Sanofi Aventis Sa | N - [(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE DERIVATIVES AND THEIR PREPARATION AND THERAPEUTIC USE |
| AU2006203845A1 (en) * | 2005-01-10 | 2006-07-13 | Alexandros Makriyannis | Novel heteropyrrole analogs acting on cannabiniod receptors |
| US8853205B2 (en) | 2005-01-10 | 2014-10-07 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
| PA8660701A1 (en) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | SMALL AGONISTS AND THEIR USES |
| FR2881744B1 (en) | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | N - [(4,5-DIPHENYL-2-THIENYL) METHYL] AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| FR2882261B1 (en) * | 2005-02-21 | 2009-02-06 | Sanofi Aventis Sa | USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES |
| KR20070104913A (en) * | 2005-02-21 | 2007-10-29 | 사노피-아벤티스 | Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes |
| FR2882264A1 (en) * | 2005-02-21 | 2006-08-25 | Sanofi Aventis Sa | Use of rimonabant and N-peperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, having cannabinoids receptor antagonistic activity, to treat and prevent type-II diabetes |
| FR2882262B1 (en) * | 2005-02-23 | 2007-04-06 | Sanofi Aventis Sa | USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF RENAL DISEASES |
| FR2882263B1 (en) * | 2005-02-23 | 2007-04-06 | Sanofi Aventis Sa | USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF RENAL DISEASES |
| FR2882931B1 (en) * | 2005-03-14 | 2007-05-18 | Sanofi Aventis Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION AN ANTAGONIST COMPOUND OF CANNABINOIDESS RECEPTORS AND AN ANTIPSYCHOTIC AGENT |
| EP1868999B1 (en) | 2005-04-06 | 2009-07-01 | F. Hoffmann-Roche AG | Pyridine-3-carboxamide derivatives as cb1 inverse agonists |
| CA2609783A1 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| GB0514739D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Therapeutic agents |
| GB0514738D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Therapeutic agents |
| CA2617654A1 (en) * | 2005-08-04 | 2007-02-08 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
| CA2518579A1 (en) * | 2005-08-05 | 2007-02-05 | University Technologies International Inc. | Method for appetite suppression |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| CN100999517B (en) * | 2006-01-11 | 2010-12-15 | 北京摩力克科技有限公司 | Pyrazole formylamine derivate, its pharmaceutical composition and preparation process |
| MX2008009354A (en) | 2006-01-18 | 2008-09-30 | Schering Corp | Cannibinoid receptor modulators. |
| MX2008010899A (en) * | 2006-02-23 | 2008-11-27 | Pfizer Ltd | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines. |
| CA2647031A1 (en) * | 2006-03-10 | 2007-09-20 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| US8722691B2 (en) | 2006-03-30 | 2014-05-13 | Irm Llc | Azolopyrimidines as inhibitors of cannabinoid 1 activity |
| CN101062919B (en) * | 2006-04-26 | 2012-08-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 4-methyl-1H-diaryl pyrromonazole derivative and medicament usage thereof |
| WO2007121687A1 (en) * | 2006-04-26 | 2007-11-01 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament |
| FR2902008A1 (en) * | 2006-06-07 | 2007-12-14 | Sanofi Aventis Sa | USE OF A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF BEGIN PROSTATIC HYPERTROPHY |
| US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| UA100497C2 (en) | 2006-09-07 | 2013-01-10 | Никомед Гмбх | Combination treatment for diabetes mellitus |
| US20100076197A1 (en) * | 2006-09-11 | 2010-03-25 | Hetero Drugs Limited | Process for rimonabant |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| US7875647B2 (en) | 2006-09-29 | 2011-01-25 | Green Cross Corporation | Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists |
| MX2009004314A (en) | 2006-11-13 | 2009-05-05 | Pfizer Prod Inc | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof. |
| FR2909090B1 (en) | 2006-11-23 | 2009-01-09 | Sanofi Aventis Sa | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO [4,3-C] PYRIDAZIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| CA2673177A1 (en) | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Modulators of cb1 receptors |
| FR2911136B1 (en) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | SUBSTITUTED N- (4-CYANO-1H-PYRAZOL-3-YL) METHYLAMINE DERIVATIVES AND THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
| GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
| US8431609B2 (en) | 2007-02-19 | 2013-04-30 | Darmesh Mahendrabhai Shah | Process for preparation of pyrazole derivatives |
| FR2913018A1 (en) * | 2007-02-23 | 2008-08-29 | Sanofi Aventis Sa | New pyrazol-3-carboxamide derivative in amorphous form comprising surinabant and rimonabant form, useful for preparing amorphous solid solution |
| US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| KR101560844B1 (en) | 2007-06-04 | 2015-10-15 | 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 | - tri-aryl compounds and compositions comprising the same |
| WO2009005671A2 (en) * | 2007-06-28 | 2009-01-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| CA2692268A1 (en) * | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
| FR2919861A1 (en) * | 2007-08-06 | 2009-02-13 | Sanofi Aventis Sa | RIMONABANT ISOPRANOL SOLVATE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| US8133904B2 (en) * | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| WO2010013240A1 (en) | 2008-07-31 | 2010-02-04 | Dekel Pharmaceuticals Ltd. | Compositions and methods for treating inflammatory disorders |
| CA2731897C (en) * | 2008-08-06 | 2013-07-02 | Pfizer Limited | Diazepine and diazocane compounds as mc4 agonists |
| WO2010079241A1 (en) * | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability |
| US10053444B2 (en) | 2009-02-19 | 2018-08-21 | University Of Connecticut | Cannabinergic nitrate esters and related analogs |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| WO2013068371A1 (en) | 2011-11-08 | 2013-05-16 | Intervet International B.V. | Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists |
| KR20160094956A (en) | 2013-11-05 | 2016-08-10 | 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 | Compounds for the treatment of diabetes and disease complications arising from same |
| CA3125847A1 (en) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Process for making biologically active compounds and intermediates thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2713225B1 (en) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | Substituted N-piperidino-3-pyrazolecarboxamide. |
| FR2692575B1 (en) | 1992-06-23 | 1995-06-30 | Sanofi Elf | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| FR2714057B1 (en) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | New derivatives of 3-pyrazolecarboxamide, process for their preparation and pharmaceutical compositions containing them. |
| FR2741621B1 (en) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| FR2789079B3 (en) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
-
1999
- 1999-08-02 FR FR9910166A patent/FR2789079B3/en not_active Expired - Lifetime
-
2000
- 2000-01-28 TR TR2001/02054T patent/TR200102054T2/en unknown
- 2000-01-28 EE EEP200100399A patent/EE04343B1/en not_active IP Right Cessation
- 2000-01-28 JP JP2000597279A patent/JP3794925B2/en not_active Expired - Fee Related
- 2000-01-28 KR KR10-2001-7009572A patent/KR100425405B1/en not_active IP Right Cessation
- 2000-01-28 DE DE60006070T patent/DE60006070T2/en not_active Expired - Lifetime
- 2000-01-28 HU HU0201278A patent/HUP0201278A3/en unknown
- 2000-01-28 RU RU2001121186/04A patent/RU2216542C2/en not_active IP Right Cessation
- 2000-01-28 CZ CZ20012697A patent/CZ297667B6/en not_active IP Right Cessation
- 2000-01-28 AU AU22989/00A patent/AU754771B2/en not_active Ceased
- 2000-01-28 NZ NZ512886A patent/NZ512886A/en not_active IP Right Cessation
- 2000-01-28 RS YUP-539/01A patent/RS50209B/en unknown
- 2000-01-28 BR BR0007895-6A patent/BR0007895A/en not_active IP Right Cessation
- 2000-01-28 US US09/890,242 patent/US6432984B1/en not_active Expired - Lifetime
- 2000-01-28 PL PL350030A patent/PL198422B1/en not_active IP Right Cessation
- 2000-01-28 EP EP00901661A patent/EP1150961B1/en not_active Expired - Lifetime
- 2000-01-28 CA CA002358885A patent/CA2358885C/en not_active Expired - Fee Related
- 2000-01-28 CN CNB008054681A patent/CN1146544C/en not_active Expired - Fee Related
- 2000-01-28 PT PT00901661T patent/PT1150961E/en unknown
- 2000-01-28 WO PCT/FR2000/000194 patent/WO2000046209A1/en active IP Right Grant
- 2000-01-28 AR ARP000100386A patent/AR020558A1/en unknown
- 2000-01-28 SK SK1087-2001A patent/SK284203B6/en not_active IP Right Cessation
- 2000-01-28 PE PE2000000066A patent/PE20001493A1/en not_active Application Discontinuation
- 2000-01-28 UA UA2001074905A patent/UA66900C2/en unknown
- 2000-01-28 AT AT00901661T patent/ATE252562T1/en active
- 2000-01-28 ES ES00901661T patent/ES2208267T3/en not_active Expired - Lifetime
- 2000-01-28 DK DK00901661T patent/DK1150961T3/en active
- 2000-01-28 ME MEP-2008-114A patent/ME00052B/en unknown
- 2000-01-28 IL IL14419800A patent/IL144198A0/en active IP Right Grant
- 2000-01-28 ME MEP-114/08A patent/MEP11408A/en unknown
- 2000-01-28 ID IDW00200101603A patent/ID29534A/en unknown
- 2000-01-31 CO CO00005429A patent/CO5160257A1/en unknown
- 2000-01-31 TW TW089101649A patent/TW581764B/en not_active IP Right Cessation
-
2001
- 2001-07-08 IL IL144198A patent/IL144198A/en not_active IP Right Cessation
- 2001-07-13 IS IS6002A patent/IS2448B/en unknown
- 2001-07-26 HR HR20010564A patent/HRP20010564B1/en not_active IP Right Cessation
- 2001-07-27 BG BG105749A patent/BG65193B1/en unknown
- 2001-07-30 NO NO20013736A patent/NO319824B1/en not_active IP Right Cessation
-
2002
- 2002-01-29 HK HK02100712A patent/HK1039329A1/en not_active IP Right Cessation
- 2002-06-07 US US10/165,140 patent/US6645985B2/en not_active Expired - Lifetime
-
2003
- 2003-06-05 US US10/455,220 patent/US20040039024A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2358885C (en) | Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them | |
| US5462960A (en) | Pyrazole-3-carboxamide derivatives, process for their preparation and pharmaceutical compositions in which they are present | |
| US7384960B2 (en) | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | |
| JP3137222B2 (en) | Substituted N-piperidino-pyrazole-3-carboxamides | |
| JP3238801B2 (en) | Novel pyrazole derivatives, methods for preparing them, and pharmaceutical compositions containing them | |
| HU225156B1 (en) | Tricyclic 1-benzylpyrazole-3-carboxylic acid derivatives, preparation of the compounds, their use and pharmaceutical compositions containing them | |
| MXPA01007781A (en) | Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them | |
| FR2789078A1 (en) | New compound N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-3-pyrazole carboxamide useful as a cannabinoid receptor antagonist, e.g. for treating eating disorders, obesity, amnesia and cognitive disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150128 |